Dexpramipexole dihydrochloride

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

多巴胺受体的部分/完全激动剂，D2S/D2L/D3/D4 的 Ki 值分别为 3.9/2.2/0.5/5.1 nM。

A partial/full agonist of dopamine receptor with Ki of 3.9/2.2/0.5/5.1 nM for D2S/D2L/D3/D4, respeectively; also possesses low/insignificant affinity (500–10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors; used for treating Parkinson's disease (PD) and restless legs syndrome (RLS).Alzheimer's Disease Phase 2 Clinical(In Vitro):Dexpramipexole has been found to have neuroprotective effects and is being investigated for treatment of amyotrophic lateral sclerosis (ALS). Dexpramipexole reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, Dexpramipexole has much lower dopamine agonist activity.

Dexpramipexole has been found to have neuroprotective effects and is being investigated for treatment of amyotrophic lateral sclerosis (ALS). Dexpramipexole reduces mitochondrial reactive oxygen species (ROS) production, inhibits the activation of apoptotic pathways, and increase cell survival in response to a variety of neurotoxins and β-amyloid neurotoxicity. Compared to the S-(-) isomer, Dexpramipexole has much lower dopamine agonist activity.

——

R)-Pramipexole | KNS-760704

GPCR/G Protein

Dopamine Receptor

Dopamine Receptor

Neurological Disease

Alzheimer Disease

104632-27-1

284.249

C10H19Cl2N3S

>98% (HPLC)

DMSO: ≥ 28 mg/mL

CCCNC1CCC2=C(C1)SC(=N2)N.Cl.Cl

2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, hydrochloride (1:2), (6R)-

(-20℃)

With Ice Pack

≥ 2 years